Literature DB >> 24676945

Chromogenic factor VIII activity assay.

Karen A Moser1, Dorothy M Adcock Funk.   

Abstract

Factor VIII (FVIII) may be measured by three different methodologies in the clinical laboratory: one-stage clotting assay, two-stage clotting assay, and chromogenic assay. These assays differ in ease of use, variety of reagents available, sensitivity to mild hemophilia A, and interference from lupus anticoagulants. This review will outline the methodology for each of the FVIII activity assays, with a discussion of assay interferences and variability. In some cases, chromogenic FVIII activity assays may be preferable to clot-based assays, and these clinical situations will be reviewed as well.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24676945     DOI: 10.1002/ajh.23723

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

1.  Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice.

Authors:  Ruo-lan Gu; Liang Liu; Liang-zhi Xie; Wen-lin Gai; Si-shuo Cao; Zhi-yun Meng; Hui Gan; Zhuo-na Wu; Jian Li; Ying Zheng; Xiao-xia Zhu; Gui-fang Dou
Journal:  Acta Pharmacol Sin       Date:  2016-01-25       Impact factor: 6.150

Review 2.  Consensus recommendations on appropriate coagulation tests during emicizumab administration in Saudi Arabia.

Authors:  Tarek Owaidah; Abdulakareem Almomen; Ahmed Tarawah; Ashraf Warsi; Fawaz Alkasim; Hazzaa Alzahrani; Mahassen Saleh; Ohoud Kashari; Wasil Jastaniah
Journal:  Am J Blood Res       Date:  2022-06-20

3.  Recombinant Factor VIII Measurement in a Hemophilia A Patient Undergoing Cardiopulmonary Bypass-Supported Cardiac Surgery.

Authors:  Jennifer Bezaire; Dorothy Thomson; Erick McNair
Journal:  J Extra Corpor Technol       Date:  2018-09

Review 4.  Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.

Authors:  Richard A Marlar; Karin Strandberg; Midori Shima; Dorothy M Adcock
Journal:  Eur J Haematol       Date:  2019-11-13       Impact factor: 2.997

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.